NEUROCRINE BIOSCIENCES INC (NBIX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 687,500 | 572,600 | 622,100 | |
| Selling, general, and administrative | 286,300 | 276,500 | 234,300 | |
| Research and development | 244,300 | 263,200 | 195,000 | |
| Acquired in-process research and development | - | 100 | 1,000 | |
| Cost of revenues | 11,300 | 9,200 | 8,000 | |
| Total operating expenses | 541,900 | 549,000 | 438,300 | |
| Operating income | 145,600 | 23,600 | 183,800 | |
| Unrealized loss on equity investments | -6,700 | -30,600 | -16,900 | |
| Investment income and other, net | 20,600 | 21,700 | 23,400 | |
| Charges associated with convertible senior notes | - | - | - | |
| Total other income (expense), net | 13,900 | -8,900 | 6,500 | |
| Income before provision for income taxes | 159,500 | 14,700 | 190,300 | |
| Provision for income taxes | 52,000 | 6,800 | 60,500 | |
| Net income | 107,500 | 7,900 | 129,800 | |
| Foreign currency translation adjustments, net of tax | -800 | -1,500 | -2,900 | |
| Unrealized gain (loss) on available-for-sale debt securities, net of tax | 2,700 | 1,700 | 9,100 | |
| Comprehensive income | 111,000 | 11,100 | 141,800 | |
| Basic (in shares) | 99,000,000 | 99,700,000 | 101,100,000 | |
| Basic (in usd per share) | 1.09 | 0.08 | 1.28 | |
| Diluted (in shares) | 101,000,000 | 102,500,000 | 104,300,000 | |
| Diluted (in usd per share) | 1.06 | 0.08 | 1.24 | |